WallStreetZenWallStreetZen

NASDAQ: VBIV
Vbi Vaccines Inc Stock

$0.58-0.02 (-3.33%)
Updated Apr 12, 2024
VBIV Price
$0.58
Fair Value Price
-$0.69
Market Cap
$13.74M
52 Week Low
$0.45
52 Week High
$3.86
P/E
-0.05x
P/B
0.69x
P/S
1.74x
PEG
N/A
Dividend Yield
N/A
Revenue
$8.12M
Earnings
-$113.96M
Gross Margin
-58.8%
Operating Margin
-1,330.66%
Profit Margin
-1,413.8%
Debt to Equity
4.07
Operating Cash Flow
-$68M
Beta
1.26
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A

VBIV Overview

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VBIV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

VBIV ($0.58) is overvalued by 184.62% relative to our estimate of its Fair Value price of -$0.69 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VBIV ($0.58) is not significantly undervalued (184.62%) relative to our estimate of its Fair Value price of -$0.69 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VBIV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VBIV due diligence checks available for Premium users.

Be the first to know about important VBIV news, forecast changes, insider trades & much more!

VBIV News

Valuation

VBIV fair value

Fair Value of VBIV stock based on Discounted Cash Flow (DCF)
Price
$0.58
Fair Value
-$0.69
Undervalued by
184.62%
VBIV ($0.58) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VBIV ($0.58) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VBIV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

VBIV price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.05x
Industry
14.72x
Market
42.64x

VBIV price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.69x
Industry
5.93x
VBIV is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

VBIV's financial health

Profit margin

Revenue
$6.6M
Net Income
-$20.4M
Profit Margin
-321.6%
VBIV's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
VBIV's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$100.8M
Liabilities
$80.9M
Debt to equity
4.07
VBIV's short-term liabilities ($77.19M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VBIV's short-term assets ($50.15M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VBIV's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
VBIV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$8.0M
Investing
-$113.0k
Financing
$22.4M
VBIV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

VBIV vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
VBIV$13.74M-3.33%-0.05x0.69x
TNXP$13.77M-4.12%-0.02x0.13x
MNPR$13.63M+1.43%-1.28x2.44x
XTLB$14.17M-5.80%-13.00x3.54x
MIRA$13.30M-8.16%-1.41x3.04x

Vbi Vaccines Stock FAQ

What is Vbi Vaccines's quote symbol?

(NASDAQ: VBIV) Vbi Vaccines trades on the NASDAQ under the ticker symbol VBIV. Vbi Vaccines stock quotes can also be displayed as NASDAQ: VBIV.

If you're new to stock investing, here's how to buy Vbi Vaccines stock.

What is the 52 week high and low for Vbi Vaccines (NASDAQ: VBIV)?

(NASDAQ: VBIV) Vbi Vaccines's 52-week high was $3.86, and its 52-week low was $0.45. It is currently -84.97% from its 52-week high and 28.89% from its 52-week low.

How much is Vbi Vaccines stock worth today?

(NASDAQ: VBIV) Vbi Vaccines currently has 23,687,695 outstanding shares. With Vbi Vaccines stock trading at $0.58 per share, the total value of Vbi Vaccines stock (market capitalization) is $13.74M.

Vbi Vaccines stock was originally listed at a price of $393.75 in Dec 31, 1997. If you had invested in Vbi Vaccines stock at $393.75, your return over the last 26 years would have been -99.85%, for an annualized return of -22.18% (not including any dividends or dividend reinvestments).

How much is Vbi Vaccines's stock price per share?

(NASDAQ: VBIV) Vbi Vaccines stock price per share is $0.58 today (as of Apr 12, 2024).

What is Vbi Vaccines's Market Cap?

(NASDAQ: VBIV) Vbi Vaccines's market cap is $13.74M, as of Apr 14, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Vbi Vaccines's market cap is calculated by multiplying VBIV's current stock price of $0.58 by VBIV's total outstanding shares of 23,687,695.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.